KPAX 002

Drug Profile

KPAX 002

Alternative Names: KPAX002

Latest Information Update: 08 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator K-PAX Pharmaceuticals
  • Class Amino acids; Phenylacetates; Piperidines
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic fatigue syndrome; Cognition disorders

Most Recent Events

  • 21 Sep 2015 K-PAX Pharmaceuticals has patent protection for KPAX 002 in USA
  • 01 Jan 2015 Phase-II clinical trials in Cognition disorders in USA (PO) (NCT02357030)
  • 01 Nov 2013 Phase-II clinical trials in Chronic fatigue syndrome in USA (PO) (NCT01966276)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top